RECRUITING

TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Official Title

A Single-arm, Open-label, Dose Escalation + Cohort Expansion Phase 1 Trial on Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Quick Facts

Study Start:2024-06-15

Study Completion:2027-06-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06088888

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Willing to participate in the study with informed consent; * At least 18 years of age at the time of screening; * Any sex; * Diagnosis of CML-CPduring the screening period; * Intolerant or resistant to TKI treatments; * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; * Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels; * Adequate renal and liver function; * Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results; * Negative blood pregnancy test results for female patients of childbearing potential. * Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.	* Exposure to other antineoplastic therapies prior to study enrollment; * Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy; * Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia); * Hematopoietic cell transplantation \< 60 days prior to the first dose; * Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy; * Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment); * Exposure to drugs related to torsade de pointes; * Cytological or pathological diagnosis of active central nervous system disorder; * Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol; * Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome; * Uncontrolled hypertension; * Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose; * Severe hemorrhagic disorders unrelated to CML; * History of pancreatitis; * History of excessive alcohol use; * History of elevation in amylase or lipase within 1 year; * Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening; * Uncontrolled hypertriglyceridemia; * Malabsorption syndrome or other illness that could affect oral absorption. * Diagnosis of another primary malignancy in the past 3 years; * Reception of major surgery within 14 days prior to the first dose; * Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment; * Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections); * Have received or will receive a COVID-19 vaccine within 14 days of study enrollment; * Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening; * Pregnant or breastfeeding female; * Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug; * Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor; * Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;

Inclusion Criteria

Exclusion Criteria

* Willing to participate in the study with informed consent;
* At least 18 years of age at the time of screening;
* Any sex;
* Diagnosis of CML-CPduring the screening period;
* Intolerant or resistant to TKI treatments;
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
* Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels;
* Adequate renal and liver function;
* Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results;
* Negative blood pregnancy test results for female patients of childbearing potential.
* Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.

* Exposure to other antineoplastic therapies prior to study enrollment;
* Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy;
* Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia);
* Hematopoietic cell transplantation \< 60 days prior to the first dose;
* Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy;
* Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment);
* Exposure to drugs related to torsade de pointes;
* Cytological or pathological diagnosis of active central nervous system disorder;
* Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol;
* Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome;
* Uncontrolled hypertension;
* Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose;
* Severe hemorrhagic disorders unrelated to CML;
* History of pancreatitis;
* History of excessive alcohol use;
* History of elevation in amylase or lipase within 1 year;
* Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening;
* Uncontrolled hypertriglyceridemia;
* Malabsorption syndrome or other illness that could affect oral absorption.
* Diagnosis of another primary malignancy in the past 3 years;
* Reception of major surgery within 14 days prior to the first dose;
* Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment;
* Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections);
* Have received or will receive a COVID-19 vaccine within 14 days of study enrollment;
* Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening;
* Pregnant or breastfeeding female;
* Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug;
* Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor;
* Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;

Contacts and Locations

Study Contact

Xinyi Zhu

CONTACT

86-13061651609

xinyi.zhu@tjrbiosciences.com

Principal Investigator

Elias Jabbour

PRINCIPAL_INVESTIGATOR

The University of Texas MD Anderson Cancer Center

Study Locations (Sites)

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

United States

Fred Hutchinson Cancer Center

Seattle, Washington, 98102

United States

Collaborators and Investigators

Sponsor: Shenzhen TargetRx, Inc.

Elias Jabbour, PRINCIPAL_INVESTIGATOR, The University of Texas MD Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-15

Study Completion Date2027-06-30

Study Record Updates

Study Start Date2024-06-15

Study Completion Date2027-06-30

Terms related to this study

Additional Relevant MeSH Terms

Chronic Myelogenous Leukemia